News & Updates
Filter by Specialty:
Local failure tied to survival in intermediate-risk PCa after definitive radiotherapy
In men with intermediate- or high-risk prostate cancer (PCa), local failure after definitive radiation therapy (RT) is indicative of survival outcomes, according to a recent study.
Local failure tied to survival in intermediate-risk PCa after definitive radiotherapy
18 Aug 2022Avelumab benefit may extend to cisplatin-unfit bladder cancer patients
The anti-PD-L1 antibody avelumab demonstrated clinical activity as first-line treatment for patients with metastatic or locally advanced urothelial carcinoma who were PD-L1-positive and ineligible for cisplatin, according to findings from the ARIES trial presented at EAU 2022.
Avelumab benefit may extend to cisplatin-unfit bladder cancer patients
08 Aug 2022Abiraterone-olaparib confers clinical benefit for mCRPC patients
The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.
Abiraterone-olaparib confers clinical benefit for mCRPC patients
04 Aug 2022GLP-1 RAs help lower serum uric acid concentration
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a drug class mainly used for the management of type 2 diabetes, significantly reduces serum uric acid (SUA) concentration, a recent study has shown.